Summary of the study samples
| Characteristics . | Study samples . |
|---|---|
| No. of BCP-ALL cases | 23∗,† |
| Mean age, y | 8.5 |
| Female/male, n | 12/11 |
| BM blasts, mean % | 89 |
| Molecular subgroup/WHO classification, no. of patients | |
| BCR::ABL1/BCP-ALL with (9;22)(q34.1;q11.2);BCR::ABL1 | 4 |
| ETV6::RUNX1/t(12;21)(p13.2;q22.1);ETV6::RUNX1 | 4 |
| HeH/hyperdiploidy | 4 |
| DUX4-r/BCP-ALL with other defined genetic abnormalities | 11 |
| scRNA-seq, no. of BCP-ALL cases (no. of cells) | 23 (149 731) |
| BCR::ABL1 | 4 (25 706) |
| ETV6::RUNX1 | 4 (29 772) |
| HeH | 4 (21 346) |
| DUX4-r | 11 (72 907) |
| scATAC-seq, no. of BCP-ALL cases (no. of nuclei) | 19 (35 225) |
| BCR::ABL1 | 3 (7 181) |
| ETV6::RUNX1 | 4 (7 712) |
| HeH | 4 (3 623) |
| DUX4-r | 8 (15 657) |
| No. of NBM samples (donors) | 9 (5) |
| MNC | 3 |
| CD34+-enriched | 3 |
| CD19+-enriched | 3 |
| scRNA-seq, no. of NBM samples (no. of cells) | 9 (38 815) |
| MNC | 3 (16 717) |
| CD34+-enriched | 3 (11 131) |
| CD19+-enriched | 3 (10 967) |
| scATAC-seq, no. of NBM samples (no. of nuclei) | 4 (6 667) |
| MNC | 3 (4 623) |
| CD34+-enriched | 1 (3 096) |
| Characteristics . | Study samples . |
|---|---|
| No. of BCP-ALL cases | 23∗,† |
| Mean age, y | 8.5 |
| Female/male, n | 12/11 |
| BM blasts, mean % | 89 |
| Molecular subgroup/WHO classification, no. of patients | |
| BCR::ABL1/BCP-ALL with (9;22)(q34.1;q11.2);BCR::ABL1 | 4 |
| ETV6::RUNX1/t(12;21)(p13.2;q22.1);ETV6::RUNX1 | 4 |
| HeH/hyperdiploidy | 4 |
| DUX4-r/BCP-ALL with other defined genetic abnormalities | 11 |
| scRNA-seq, no. of BCP-ALL cases (no. of cells) | 23 (149 731) |
| BCR::ABL1 | 4 (25 706) |
| ETV6::RUNX1 | 4 (29 772) |
| HeH | 4 (21 346) |
| DUX4-r | 11 (72 907) |
| scATAC-seq, no. of BCP-ALL cases (no. of nuclei) | 19 (35 225) |
| BCR::ABL1 | 3 (7 181) |
| ETV6::RUNX1 | 4 (7 712) |
| HeH | 4 (3 623) |
| DUX4-r | 8 (15 657) |
| No. of NBM samples (donors) | 9 (5) |
| MNC | 3 |
| CD34+-enriched | 3 |
| CD19+-enriched | 3 |
| scRNA-seq, no. of NBM samples (no. of cells) | 9 (38 815) |
| MNC | 3 (16 717) |
| CD34+-enriched | 3 (11 131) |
| CD19+-enriched | 3 (10 967) |
| scATAC-seq, no. of NBM samples (no. of nuclei) | 4 (6 667) |
| MNC | 3 (4 623) |
| CD34+-enriched | 1 (3 096) |